Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

This is a multi-center, open-label, Phase I/II clinical study of MCLA-129 as monotherapy in patients with advanced solid tumors to evaluate the safety, pharmacokinetic characteristics and antitumor activity of MCLA-129.

Trial Details

NCT ID
NCT04930432
Phase
PHASE1 / PHASE2
Sponsor
Betta Pharmaceuticals Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • MCLA-129
Locations (sample)
  • Baoding, China|38.87288,115.46246
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723
  • Bengbu, China|32.94083,117.36083
  • Cangzhou, China|38.31124,116.85334

Key Eligibility Criteria

  • Subjects are ≥ 18 years of age, regardless of gender.
  • Subjects must have histologically or cytologically confirmed metastatic or unresectable advanced NSCLC or other solid tumors (including but not lim…
  • For Part 1, subjects must be diagnosed with EGFR positive and/or MET positive by testing.
  • For patients with advanced NSCLC, EGFR positive is defined as: EGFR mutation or EGFR amplification. MET positive is defined as: MET amplification o…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →